Introduction 1
Enteroendocrine cells (EEC) are specialised hormone secreting cells in the intestinal epithelium which 2 monitor the quality and quantity of ingested foods. They produce at least 20 different hormones, mostly 3 peptides, that act in concert to coordinate digestion, peripheral nutrient disposal and appetite through 4 actions at local and distant target tissues. In the field of human metabolism, glucagon-like peptide-1 (GLP-1) 5 and peptideYY (PYY) have raised particular interest because of their central and pancreatic actions controlling 6 food intake and insulin secretion. GLP-1 based drugs are widely used for the treatment of diabetes and 7 obesity, and new gut hormone based therapeutics are under development, aiming to mimic the unrivalled 8 effectiveness of gastric bypass surgery on weight loss and type 2 diabetes resolution(2). 9
Our understanding of the physiology and pharmacology of human EECs is currently limited by a lack of 10 methods to identify and characterise this scattered cell population which only comprises ~1% of the intestinal 11 epithelium(3). By contrast, recent years have witnessed substantial progress in our understanding of murine 12 EEC physiology, facilitated by the generation of transgenic mice with fluorescently labelled EECs that enable 13 cell identification and functional characterisation through a range of approaches including fluorescence-14 activated cell sorting (FACS), transcriptomics and live cell imaging (3) (4) (5) (6) (7) (8) . The lack of an evidence-based 15 platform for predicting the translatability of these findings from mouse to human represents, however, a 16 significant obstacle in drug discovery programmes. Whilst G-protein coupled receptors (GPCRs) that have 17 been identified and characterised in murine EECs represent promising candidates for therapeutic approaches 18 to enhance endogenous gut hormone secretion, early validation in a human model is strongly advisable(9). 19
Our objective was to compare mouse and human EECs at the transcriptomic and peptidomic levels. For 20 transcriptomics, we purified and RNA sequenced two subsets of human EECs distinguished by their 21 production (or not) of GLP-1, and compared the results with matching murine cell populations purified from 22 transgenic mouse models. Sequencing depth in both species was sufficient to enable the identification of low 23 abundance transcripts such as GPCRs and ion channels. We optimised protocols for peptide extraction and 24 liquid chromatography / tandem mass spectrometric (LC-MS/MS) analysis of mucosal tissue homogenates, 25 and identified exact sequences of the different gut peptides produced, and their relative quantities along the 1 length of the GI tract in human and mouse. 2 3 Results 1 Cell and RNA collection for transcriptomics 2 Tissue was obtained from 11 human participants recruited from sites in Cambridge and Paris (Supplementary 3 table 1). Jejunum samples were collected from all participants, and paired ileum and jejunum were obtained 4 from 2 transplant donors. Tissue pieces were digested, paraformaldehyde (PFA)-fixed and stained for 5
Chromogranin A (CHGA) and Secretogranin 2 (SCG2) as general markers for EECs, and for GLP-1 as a marker 6 of the EEC-subpopulation known as L-cells. By flow cytometry (Supplementary Figure 1A -C), we collected 7 pooled cell populations that were (i) positive for CHGA, SCG2 and GLP-1 (henceforth named GCG+), (ii) 8 positive for CHGA and SCG2 but negative for GLP-1 (henceforth named GCG-), and (iii) negative for all 3 9 markers (i.e. non-endocrine lineage cells, henceforth named negative). The GCG+ (L-cell) population 10 represented ~0.2% of all single cells examined, and the ratio of GCG+ to GCG-cells was ~1: 5. 11 For the cross-species comparison, we collected unfixed murine EEC populations from the upper small 12 intestine of the mouse strain GLU-Venus (n=3) to identify Gcg-expressing L-cells (Supplementary Figure 1E -13 G) (8) , and of NeuroD1-Cre/EYFP mice(7) (n=3) to identify the total EEC population (Supplementary Figure 1I -14 K). NeuroD1 is a well characterised EEC transcription factor found in the same cells as Chga in a previous 15 single cell analysis of murine EECs (10) . GLU-Venus positive cells represented ~0.2% of singlets, and NeuroD1 16 positive cells ~0.6% of singlets. 17 RNA extracted from the purified fixed human cell populations had RIN values of only 2-3, with most RNA 18 fragments being 25-500 bases in length (Supplementary Figure 1D ), but we hypothesised that the short 19 fragments might be sufficient for RNA sequencing using random primers. After RNA sequencing there were 20 high proportions of unmatched reads (up to 50% in some samples), likely due to the PFA modified input RNA, 21 but in all cases sequencing was achieved to a depth of at least 8.5x10 5 matched reads per sample. RNAs from 22 murine cell populations purified without fixation had RIN values of >7 ( Supplementary Figure 1H ,L) and were 23 sequenced to >5x10 6 aligned reads per sample. 24
Transcriptomics of human EEC populations 25
GIPR, AVPR1B, OXTR, CRHR2, RXFP4, GLP1R, NPY1R, CALCR, GALR1 and SCTR. Two opioid receptors, OPRK1 1 and OPRD1, not previously described as active in the gastrointestinal tract were identified in EECs, alongside 2 the oestrogen receptor GPER1 and prostaglandin receptors PTGDR2 and PTGER3. At least four orphan GPCRs 3 were differentially expressed in human EECs: GPR148, GPR160, GPR173 and GPR179, hinting to as yet 4 undescribed pathways that may control gut hormone secretion. 5
Transcripts for a range of ion channel subunits were enriched in human EECs ( Supplementary Figure 2) , 6 consistent with previous reports that murine L-cells and enterochromaffin cells are electrically active. Human 7 GCG+ and GCG-EECs were particularly enriched for the voltage-gated calcium channel subunits CACNA1A 8 (P/Q-type), CACNA1C and CACNA1D (L-type), and CACNA1H (T-type)(17), and the voltage-gated sodium 9 channel subunits SCN3A and SCN8A. TRPA1, previously described to stimulate GLP-1 and 5-HT secretion in 10 mouse, was enriched in both EEC populations (18, 19) , as was the amiloride/acid sensitive ion channel ASIC5, 11 and the KATP channel subunits KCNJ11 and ABCC8 (8, 20) . 12
Transcription factor profiling of human GCG+ and GCG-cells is also shown in Supplementary Figure 2 . 13
Comparison of human jejunum vs ileum EEC transcriptomes 14
PCA of the 3 cell populations from each of the 2 matched human jejunum and ileum samples separated EECs 15 from negative cells on the first component and the anatomical location of GCG+ and GCG-cells on the second 16 component ( Figure 3A ). This distinction was driven by a low number of differentially expressed genes, 279 in 17 GCG+ cells and 120 in GCG-cells, when analysed pairwise using a DESEQ2 model. Notable differentially 18 expressed transcripts that were higher in jejunal than ileal EECs (GCG+ or GCG-) included GIP, CCK, SST, MLN, 19 SCT, GHRH, ASIC5, and TRPA1; whereas transcripts higher in ileal than jejunal EECs included GCG, NTS and 20 TAC1 (Figure 3 ,B,C). 21
Comparison of human vs mouse EEC transcriptomes 22
We compared human jejunal GCG+ cells with murine upper small intestinal GLU-Venus cells, representing 23 the GLP-1 secreting L-cell populations from each species (Figure 4 ). Only genes with 1:1 homology annotated 24 in Ensembl were included, and genes annotated as ribosomal, mitochondrial and small-nuclear were 25 excluded, giving a total of 15,507 genes for comparison. Log-log plots of normalised gene expression 1 indicated a strong correlation between the two species (R 2 =0.73; Figure 4 ). Of the 354 genes lying outside 2 the 99% confidence interval of the linear model of human versus mouse, notable genes more highly 3 expressed in human than mouse GCG+ cells included GIP, CHGA, ASIC5, GIPR, GPR142, SCTR, PTH2R, CHRNA5 4 and OPRK1; whereas genes more highly expressed in mouse GCG+ cells included Gpr174, Gpr171, Ghr, Grpr, 5
Ptger1, Cnr1, Insl5, Gpr22 and Ghrl. 6
Human jejunal GCG-cells, representing the wider murine EEC population (although depleted of L-cells) were 7 compared with murine NeuroD1-positive cells, revealing a strong correlation between these human and 8 murine EEC populations (R 2 =0.74; Figure 5 ). Of the 380 genes lying outside the 99% confidence interval of 9 the linear model for this comparison, notable genes more highly expressed in human than murine EECs 10 included GIPR, SCTR,, GHRH, OPRK1, PTH2R and TRPV6, and in murine compared with human cells included 11
Ghrl, Tac1, Iapp, Gpr22, Gast, Ptger1, Grpr and Ghr. 12
Species-comparative data for subgroups of genes in L-cells and the total EEC population, separated by their 13 annotated roles as hormones, GPCRs, ion channels and transcription factors, are represented in Figures 5 14 and 6, in which the colour code additionally indicates whether the genes were more than four fold enriched 15 and significantly likely to be differentially expressed based on the DESEQ2 model (adjusted P <= 0.1) in EECs 16 compared with negative cells in one or both species. 17
Peptidomic analysis by LC-MS 18
Peptide extraction and LC-MS protocols for analysis of fresh intestinal mucosal samples were optimised for 19 maximum peptide retrieval and identification ( Supplementary Figure 3) , and enabled reliable detection and 20 sequencing of peptides up to 65 amino acids in length. In the first instance, tissue samples were analysed by 21 nano LC-MS/MS and compared between human jejunum (n=4) and mouse mid-small intestine (n=4). 22
Peptides were assigned to their parental proteins by Peaks software, and were found to include known EEC 23 prohormones, granins and enteric neuronal signalling peptides as well as peptides derived from a variety of 24 house-keeping proteins that likely reflected the occurrence of some tissue damage/degradation prior to 25 homogenisation. Of the 463 and 705 different proteins matched in human and mouse respectively, 234 were 26 common between the two species, and showed good correlation (R 2 = 0.54, Figure 6A ). To identify candidate 1 EEC-derived peptides, we restricted the analysis to peptides originating from genes that in the transcriptomic 2 analysis showed >4-fold higher expression in at least one EEC sample compared with the corresponding 3 negative cell population ( Figure 6B ). The known gut hormone genes and members of the chromogranin family 4 were mostly common to mouse and human, but motilin and ghrelin were found in human but not mouse 5 jejunum, which is interesting, as the transcriptomic data identified GHRL to be preferentially expressed in 6 mouse over human jejunum. A few peptides were derived from proteins not previously known to have 7 signalling roles, but further studies will be needed to determine whether these exhibit bioactivity or simply 8 reflect peptides released from EECs during tissue degradation. To search for novel candidate peptide 9 hormones, we also examined the transcriptomic data for unannotated transcripts that had a base mean value 10 >100 and were >16 fold more highly expressed in EECs than control cells. This analysis identified MIR7-11 3HG(21), C1orf127 and C6orf141, but we were unable to detect corresponding peptides in the LC-MS data. 12
We then performed a longitudinal LC-MS analysis of known bioactive peptides along the length of the mouse 13 and human GI tract. Sequential samples were taken at 5cm intervals from the stomach to the rectum in mice 14 (n=4 for each location), and human biopsies were analysed from the stomach (n=5), duodenum (n=9), 15 jejunum (n=2), ileum (n=4), proximal colon (n=3), sigmoid colon (n=5) and rectum (n=3). Most EEC peptides 16 were identifiable in their known bioactive forms but fragments of pro-CCK mostly lacked the C-terminally 17 active 8 amino acids, perhaps reflecting an extraction artefact as CCK is known to be highly labile under 18 different conditions and our method was not optimized for very small peptides such as CCK-8. We therefore 19 used a robustly present peptide from the prohormone, CCK21-44, as a surrogate of CCK production. Peptides 20 were depicted in separate heatmaps for mouse and human (Figure 7 ), divided into their origin from EEC 21 prohormones, granins and non-EECs (likely reflecting enteric neural peptides). The observed longitudinal 22 profiles broadly mirror historical immuno-staining patterns(22) but additionally provide details of the exact 23 peptide sequences and their post-translational modifications that cannot be deduced from antibody staining. 24
The human and mouse profiles were similar for most EEC peptides, with the notable exceptions that CCK, 25 NTS and SCT extended into the colon only in mice, and that Gastrin and Ghrelin could be detected in human 26 but not mouse proximal small intestine. Of the non-EEC peptides, NMU and galanin were found along the full 27 length of mouse small and large intestine but in human NMU was largely restricted to the small intestine and 1 galanin to the distal small intestine and colon/rectum. 2 3 Discussion 1 By RNA sequencing of fixed, FACS-purified cells from the human gut, we report here the transcriptome of 2 human L-cells and the wider EEC population, and a between-species comparison showing a strong similarity 3 with matching cells from the mouse. LC-MS based peptidomic analysis revealed longitudinal gradients of a 4 range of EEC peptides, including their sequences and post-translational modifications, along the length of 5 the human and mouse GI tract. The amalgamated transcriptomic and peptidomic picture provides a unique 6 insight into the sensory apparatus and hormonal secretory profile of human EECs, and the extent to which 7 the mouse is a valid model for studying the human enteroendocrine system. 8
The study is limited by many of the same challenges that have consistently hindered RNA and peptidomic 9 analyses. We relied on good quality internal epitopes to purify human EECs for transcriptomics, but this 10 required cell fixation and permeabilisation prior to cell separation by flow cytometry. The available RNA 11 extraction and sequencing kits were only just technically capable of dealing with PFA-modified RNA and 12 although the resulting high throughput sequencing consequently had a lower than desired mapping rate the 13 read depth was sufficient for detection of low abundance mRNAs such as those encoding receptors and ion 14 channels. The transcriptomes of human L-cells and GCG-EECs mapped robustly onto the homologous RNAseq 15 data from freshly purified matching murine cell populations. Genes without a 1:1 homology between species 16 or that were not protein encoding were excluded from the comparative analysis, but can be examined in the 17 raw deposited datasets. An alternative transcriptomic approach we could have used that would also not 18 depend on the availability of genetically labelled models is single cell RNA sequencing of large numbers of 19 dissociated cells, as recently applied to murine intestinal organoids (10) . Although EECs accounted for only a 20 small percentage of the total cell count, they were readily identifiable from their transcriptomic 21 signatures (10) . This approach could be extended to human organoids or fresh human tissue, but the potential 22 influence of prolonged organoid culture conditions on the cell transcriptome still needs to be established and 23 the outputs of most single cell RNA sequencing methods are currently limited by a read-depth that precludes 24 reliable quantification of low-abundance transcripts. 25
Although we separately RNA sequenced jejunal samples from 11 humans with varying BMI, we were unable 1 to detect any effect of BMI on the EEC transcriptome. Tissue samples, were, however, collected and sorted 2 in both France and the UK where pre-operative dietary intakes were likely quite different. As the high BMI 3 samples largely originated from the French site and we accounted for the donor location when constructing 4 the models of enriched transcripts, the study was insufficiently powered to detect small differences 5 attributable to obesity. We cannot therefore exclude the possibilities that altered EEC function might arise 6 as a result of obesity or variation in dietary intake, or contribute to the causation of obesity in a subset of 7 people. 8
GPCRs that are strongly and specifically expressed in EECs underlie some of the key sensory roles of these 9 cell types and deserve consideration as candidate drug targets for enhancing gut hormone secretion as a 10 therapy for type 2 diabetes and obesity. The GPCR repertoire of human EECs largely mirrored their well-11 studied murine counterparts(9, 23-25), including expression of receptors for amino acids (CASR, GPR142), 12 triglyceride digestion products (FFAR1, FFAR4, GPR119) and bile acids (GPBAR1), as well as for hormones 13 such as somatostatin (SSTR1, SSTR2, SSTR5), GIP (GIPR) and arginine vasopressin (AVPR1B). Interestingly, 14
GPR142 was highly expressed in human EECs, supporting current studies looking to exploit its ability to 15 stimulate both insulin and incretin hormone secretion(24). 16
RNAseq analysis revealed expression in human and mouse EECs of genes encoding known gut peptides, as 17 well as several putative hormones previously described in the gut or elsewhere. Of the hormone-encoding 18 genes with a 1:1 homology between species, there was a good correlation between the expression profiles 19 of mouse and human. Motilin was expressed in human but not murine EECs, consistent with previous 20 literature(15). Our optimised peptide extraction protocol combined with nano-LC-MS analysis enabled 21 identification of the exact peptide sequences biosynthesised in human and mouse intestinal mucosa, 22
including post-translational modifications, for peptides from ~8-10 to a maximum length of 65 amino acids. 23
From the proglucagon gene, for example, we detected multiple processed and pre-processed products, 24
including GRPP, oxyntomodulin, GLP-17-36 amide, GLP-17-37, GLP-11-37, IP131-142, IP-GLP2 and GLP-2. Intact 25 (pancreatic-type) glucagon was detected in samples from the mouse stomach, but was undetectable in the 26 remainder of the intestine and colon from both species, conflicting with recent suggestions that the small 1 intestine can secrete intact glucagon(26), but consistent with our own recent findings that post-prandial 2 glucagon concentrations were not altered following gastric bypass surgery in lean subjects despite dramatic 3 increases in GLP-1(27). Whether the gut might adapt to produce glucagon in pathological conditions such as 4 obesity or type 2 diabetes cannot be concluded from our data. In addition to the set of well-recognised gut 5 hormones, LC-MS also identified some additional peptides encoded by EEC-enriched genes, including 6 peptides derived from PCSK1N, chromogranins and secretogranins. Whether any of these have specific 7 physiological roles or are simply inactive by-products of enzymatic processing of the contents of secretory 8 vesicles, requires further evaluation. 9
Mapping of gut hormone production along the GI tract length has previously been performed using immuno-10 staining methods and extraction/immuno-assays for specific peptides(22, 28). Immuno-staining relies on the 11 detection of all antigenic sequences binding to a primary antibody and is a reliable method for localising cells 12 producing any given prohormone but cannot generally distinguish whether the prohormone was processed 13 or unprocessed, or post-translationally modified. Nevertheless, immunostaining methods have resulted in 14 longitudinal maps of EEC sub-types producing different prohormones(22). Our LC-MS method provides a 15 surprisingly robust mirror of these immuno-staining maps, whilst assigning an exact peptide sequence to 16 each identified peptide, clearly distinguishing e.g. oxyntomodulin from glucagon, and PYY1-36 from PYY3-36, 17 despite these peptide pairs differing only by extensions of a few amino acids at the C and N-terminus, 18
respectively. The method also benefits from being unbiased, providing MS-based identification of all peaks 19 triggered from the liquid chromatography separation, rather than analysing only a sub-group of specified 20 peptide sequences. Interestingly we identified acylated as well as non-acylated ghrelin from the human 21 jejunum despite our previous finding that plasma acylated ghrelin levels were undetectable in humans after 22 total gastrectomy(27). We were surprised to find high levels of PYY3-36 as well as PYY1-36 in tissue 23
homogenates, suggesting that dipeptidyl-peptidases (DPP) are active within L-cells themselves, whereas GLP-24 1(7-36amide) was much more abundant than GLP-1(9-36amide), indicating they had not been subject to DPP 25 cleavage. Why GLP-1 but not PYY seems protected from DPP-mediated processing in L-cells, despite both 26 peptides being located in the same vesicular pool (manuscript under preparation), remains unclear. 27 1 In summary, we have developed techniques for RNA sequencing of purified human EECs, and for peptidomic 2 analysis of mucosal homogenates using LC-MS. Comparison of the human and mouse EEC transcriptomes 3 revealed strong global similarities between the two species. Variation at the level of a few key individual 4 genes could, however, have profound implications for the use of mouse as a model species in drug 5 development programmes targeting specific receptors. Our mouse/human comparative datasets provide 6 tools for confirming the validity of using mouse as a model for investigating given signalling pathways and 7 receptors or peptide processing in humans, and the human EEC GPCR-ome can be used independently as a 8 potential source of drug targets in the human enteroendocrine system. Longitudinal peptide mapping of the 9 GI tract by LC-MS is a key step towards understanding the metabolic benefits of gastric bypass surgery, as 10 the surgical procedures result in a shift in the location of nutrient digestion and absorption to more distal 11 regions of the small intestine, with consequent stimulation of the more distal EEC population and release of 12 their distinct profiles of peptide hormones. Devising strategies to mimic gastric bypass surgery using 13 injectable peptide mimetics or through stimulation of the endogenous EEC population is a key but highly 14 topical challenge for industry and academia alike. with modifications to the protocol as below. The FACS sorted cell suspension was centrifuged at 3000g for 5 23 minutes at 4 o C and the pellet resuspended in 200µl digestion buffer with 4µl protease and incubated at 50 o C 24 for 3 hours. The solution was then stored at -70 o C for at least 12 hours prior to further extraction. After 25 thawing, RNA was extracted using the manufacturer's protocol with the exception of performing 2x 60µl 1 elutions from the filter column in the final step. 2
The RNA solution was concentrated using a RNEasy Minelute cleanup kit (Qiagen, Hilden, Germany). RNA 3 aliquots were diluted to 200µl with nuclease free water. The standard manufacturer's protocol was followed 4 with the exception that 700µl, not 500µl, of 100% ethanol was added to the solution in step two, to generate 5 optimum binding conditions for the PFA fragmented RNA. RNA concentration and quality was analysed using 6 an Agilent 2100 Bioanalyser (Agilent, CA, USA). 7
Sequencing 8 cDNA libraries were created using the Clontech SMARTer Stranded Total RNA-Seq Kit -Pico Input Mammalian 9 v1 (Takara Bio, USA). RNA input quantity was 5ng and the non-fragmentation protocol was used. The 10 standard manufacturer's protocol was followed with the exception that 175µl of AMPure beads were used 11 for the final bead purification to ensure recovery of the small fragments of RNA arising from PFA fixation. 12
Sixteen PCR cycles were used for amplification. 13 50 base single-end sequencing was performed using an Illumina HiSEQ 4000 at the CRUK Cambridge Institute 14 Genomics Core. 15
Mouse transcriptome 16

Sample collection and preparation for FACS 17
Female NeuroD1-Cre/EYFP (mixed background: 3-10 generations back-crossed with C57BL6) and GLU-Venus 18 mice (C57BL6)(7, 8)aged 8-10 weeks were killed by cervical dislocation (n=3 each). Diced mucosa from the 19 proximal 10cm of small intestine was digested twice in 0.1% w/v collagenase XI in HBSS at 37 o C for 30 minutes 20 each. Cells were pelleted by centrifugation at 100g for 1 minute, triturated and passed through a 50µm filter. 21
Cells were stained with DAPI (1µg/ml) for 5 minutes at room temperature, washed twice and sorted in HBSS 22 on a FACSJazz sorter at the Cambridge NIHR BRC cell phenotyping hub. 23
FACS and RNA extraction 24
All positive cells, and 20,000 negative cells were collected separately into aliquots of 500µl of buffer RLT+ 1 (Qiagen), with 143mM β-mercaptoethanol. RNA was extracted using a RNeasy Micro plus kit (Qiagen) and 2 quantified using an Agilent 2100 Bioanalyser 3
Sequencing 4 2ng of each RNA was used for cDNA amplification by SPIA amplification using the Ovation RNAseq system V2 5 kit (Nugen, CA, USA). 1g of cDNA was then fragmented to ~200bp by sonication (Diagenode, Liege, Belgium) 6 and adaptors for the indexing were added using the Ovation Rapid DR multiplex 1-96 kit. Samples were 7 pooled and concentrated together with a MinElute column (Qiagen) to reach a concentration of 10nM. Single 8 end 50 base sequencing was performed at the CRUK Cambridge Institute Genomics Core with an Illumina 9 Hiseq4000. 10
RNAseq pipeline 11
Quality control and trimming of adaptors was performed using FastQC(30). Sequenced transcripts were 12 mapped to the human (GRCh37) and mouse (GRCm38) genomes using TopHat 2.1.0 and raw counts 13 generated using Cufflinks 2.2.1(31-33). Differential gene expression analysis was performed in RStudio using 14 DESEQ2(11). Gene annotation was pulled from the Ensembl dataset held in BioMart(31). Receptor and ion 15 channel lists were generated from the IUPHAR "targets and families" list(34). Graphical output used ggplot2 16 and pheatmap in RStudio(35). 17
Comparative transcriptomics 18
Mouse and human data sets were compared using only the 15,507 genes present in both datasets, not 19 annotated as ribosomal, mitochondrial or small-nuclear and described with one-to-one homology according 20 to the Ensembl mouse-human homology dataset(31). Normalised CPM (counts per million) were generated 21 from the respective DESEQ2 models and compared for the human GCG+ population versus the murine GLU-22
Venus population and the human GCG-population versus the murine NeuroD1 population. Linear models 23 were generated of the log10 CPM of the human vs murine datasets by a total least squares strategy, 99% 24 confidence intervals calculated and the outliers hand searched for relevant genes. 25
Examining just the human samples, DESEQ2 models were generated for the following sets of jejunum 1 samples: GCG+ versus negative; GCG-versus negative; GCG+ versus GCG-; GCG+ lean versus obese; GCG-2 lean versus obese. Participant paired DESEQ2 analyses were also performed comparing GCG+ and GCG-3 populations from the jejunum and ileum of the two transplant donor participants, for whom there were 4 matched jejunum and ileum samples. An adjusted P value of <=.1 was defined as the cut off for statistical 5 significance when examining for differential gene expression between populations. 6
Tissue homogenates 7
Small pieces (~2x2mm, 15-45 mg) of mucosa from different regions of the human GI tract or from every 5cm 8 of the GI tract from C57BL6 mice were homogenised in 250µl of 6M guanidine hydrochloride (Sigma-Aldrich) 9
with Lyzing MatrixD (MPbio), in a FastPrep-24 for 4x40s at 6ms -1 . Samples were stored at -70C before further 10 processing. Proteins were precipitated by adding 80% acetonitrile in water then centrifuged at 12000g at 4 o C 11 for 5 minutes. The aqueous phase containing the peptides was collected, dried on a centrifugal vacuum 12 concentrator and stored at -70 o C before analysis 13
Mass spectrometry 14
Samples were extracted using a Waters HLB μElution solid-phase extraction (SPE) plate (Waters, MA, USA) 15 after being resuspended in 500L 0.1% v/v formic acid in water as described previously and analysed after 16 reduction/alkylation(36). Human homogenates and mouse homogenates for interspecies comparison were 17 analysed using nano-flow based separation and electrospray approaches on a Thermo Fisher Ultimate 3000 18 nano LC system coupled to a Q Exactive Plus Orbitrap mass spectrometer (ThermoScientific). High-flow 19 separation for the longitudinal mouse analysis was as previously described (36 Peptidomics is a relatively new and under-developed field within proteomics, despite the varied and 2 significant roles of peptides as signalling molecules in many organisms. Peptides, due to their small size in 3 comparison to proteins, have specific properties that can be used to extract and analyse them intact by mass-4 spectrometry, giving information about their exact processing and post-translational modifications. Several 5 methods to extract peptides from different tissues or fluids have been published, but none was developed 6 to study intestinal tissues and the large variety of hormone peptides they produce. 7
Peptide extraction and purification for LC-MS/MS studies initially requires the complete disruption of the 8 tissue of interest while inhibiting all protease activity. This is to avoid contamination with degradation 9 products of larger proteins as well as degradation of the peptides of interest. The low-molecular weight 10 proteins and peptides must then be separated from the rest of the proteins and other molecules. We 11 compared several methods adapted from the literature to develop a robust and reliable method to quantify 12 peptide levels from intestinal tissues. Methods tested for tissue lysis and protein extraction included tissue 13 homogenization in 0.25% acetic acid, 8M urea, 90% methanol with 1% acetic acid, guanidine hydrochloride 14 or 80% acetonitrile, or using Trizol to extract both proteins and peptides from the same sample 1-4 Peptides 15 were separated from proteins using either 10kDa molecular weight cut-off filters or 80% acetonitrile. Samples 16 were finally purified using SPE columns, dried and reduced alkylated before being analysed by mass-17 spectrometry. 18
The different methods allowed the detection of many unique peptides by LC-MS/MS with an important 19 variability between the different methods, from 1778 unique peptides for the extraction using 8M urea to 20 25 with 90% methanol/1% acetic acid. Many corresponded to fragments of longer peptides or proteins and 21 could represent degradation products, coming either from the protein turn-over of the tissue or degradation 22 happening during sample preparation. However, most of the peptides were unique to the extraction method 23 ( Supp Fig 2a) , due to their different chemical properties and also due to different degradation levels. Focusing 24 on the analysis of the classical gut peptide hormones significantly reduced the number of hits, and clearly 25 showed that most of the expected intact peptides were detected using the guanidine HCl extraction method 26 (Supp Fig2b). In addition to improving the number of detected hormone peptides, the guanidine HCl 27 extraction method showed the highest levels of these peptides when quantified ( Supp Fig 2c) . Urea and Trizol 28 extraction were the second best methods for peptide levels and variety of peptide hormones extracted, and 29 tissue homogenization using Trizol can be a reliable technique to extract both RNA and peptides from a same 30 sample. We also compared peptide extraction from the proteins using either protein precipitation with 80% 31 ACN or using 10kDa filters, the latter resulting in the loss of many peptides and decreased levels (Supp Fig  32   2c ). 33
We then confirmed the reproducibility of the guanidine HCl +80% ACN extraction method, as the %CV from 1 5 replicates repeated twice from different mice was around 20% for most of the peptides, with higher %CV 2 for peptides detected with lower abundance (Supp Fig 2d) , and we could also show that peptide 3 quantification was linear with the amount of starting material in a range from 2 to 40 mg ( Supp Fig 2e) , 4 indicating that tissue weight can be a satisfactory normalisation factor to compare different samples. 5
Tissue homogenization in guanidine HCl followed by protein precipitation with 80% acetonitrile is therefore 6 a promising method to extract peptides from intestinal tissue for mass-spectrometry analysis, allowing the 7 detection a large range of peptides and their robust quantification. 8 9
Homogenization optimization 10
Small pieces of mouse jejunal mucosa of similar size (~40mg) were homogenized in different conditions in 11 duplicates with lysing Matrix D using a FastPrep-24 for 4 x 40s at 6ms -1 , and peptide extracted before being 12 dried on a centrifugal concentrator. Samples were resuspended in 500L 0.1% aqueous formic acid and 13 purified by solid-phase extraction using a Waters HLB μElution solid-phase extraction (SPE) plate as 14 described. Samples were analysed using high-flow rate based LC-MS method as described before. 15
For the acetic acid, guanidine HCl and urea extractions, tissues were directly incubated in 300L of the lysing 16 solution (0.25% acetic acid aqueous, guanidine HCl 6M or urea 8M) and homogenized. 200L of the 17 homogenate was collected into a new tube after centrifugation to remove tissue debris and lysing matrix 18 (5min, 2000g, 4˚C). 80% acetonitrile (800L) was added to precipitate the proteins and peptides in solution 19 were collected following centrifugation (10min, 12,000g, 4˚C). For the guanidine HCl homogenates, addition 20 of 80% acetonitrile induced a separation between an organic phase (top) and aqueous phase (bottom) in 21 addition to the protein precipitation, with the peptides in the aqueous phase (data not shown). Peptides 22 from guanidine HCl homogenization were also extracted using a Vivaspin 500 MCWO 10kDa (GE-healthcare) 23 instead of using 80% ACN, collecting the flow-through after a 30 minutes spin at 16,000g at 4˚C. Flow-through 24 was then acidified adding 10% formic acid solution and extracted by SPE. 25
For the 80% ACN and methanol/acetic acid extraction, tissues were directly homogenized in 80% acetonitrile 26 aqueous or 90% methanol 1% aqueous acetic acid, 200L of homogenate was recovered from the lysing D 27 matrix and spun at 12,000g at 4˚C for 10 minutes to separate the precipitated proteins. Peptides in 28 supernatant were transferred to a new tube and dried before SPE extraction as previously. 29
For the Trizol extraction, tissue was homogenized in 500L Trizol and the homogenates transferred to a new 30 tube. 100L chloroform was added and mixed vigorously and sample centrifuged after 10min incubation at 31 RT (15min, 12,000g, 4˚C). The upper phase (aqueous) was then transferred to a new tube (from which RNA 32 can be extracted using standard methods), 800uL 80% ACN was added to precipitate any remaining proteins 33 1 2 Figure legend (Suppl fig 3) . a and b: Venn diagrams showing the total number of unique peptides (a) and the number of unique peptides matching classical hormone peptides (b) found in the different methods for peptide extraction. c: Quantification of gut hormone peptides using different extraction methods, normalised by tissue weight. Data is represented as mean +/-SD from 2 replicates. d: Quantification variability for different peptides measured from 10 homogenates from 2 different mice. Data is the mean value +/-SD and values indicated above are the %CV. e: Raw peak area of peptide quantification for different samples spanning different weights from 2 to 40 mg plotted against the tissue weight. Linear regression is plotted, showing a good correlation between tissue weight and peptide quantification. 
